Arcus Biosciences, Inc.
NYSE:RCUSBiotechnology
-$0.09 today
- Market cap
- $2.27B
- Beta
- 0.84
- P/E (TTM)
- -8.2
- EPS (TTM)
- -$2.94
Volume 1.97M
Average 1.17M
RCUS Pre-Tax Margin
Income before tax as a percentage of revenue.
Arcus Biosciences, Inc.NYSE: RCUS
Pre-Tax Margin · Q2 FY2026 · quarter ended Jun 2026
Pre-tax margin narrows to -222.0%
Pre-tax margin was -222.0% in Q2 FY2026, down 217.0 pp from a year earlier. On a trailing-twelve-month basis it was -386.3%, down 269.5 pp year over year. Over 3 fiscal years it widened by 94.6 pp.
Context
- Pre-tax margin widened in 1 of the last 3 fiscal years.
Sources:Income StatementText generated from reported figures; not investment advice.
Pre-Tax Margin history
Percent of revenue · from the income statement
- Latest · FY2025
- -142.9%
- Year-over-year change
- -33.2pp
| Period | Period end | Pre-Tax Margin | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | -142.9% | -33.2pp |
| FY2024 | 2024-12-31 | -109.7% | +147.6pp |
| FY2023 | 2023-12-31 | -257.3% | -19.8pp |
| FY2022 | 2022-12-31 | -237.5% | -251.9pp |
| FY2021 | 2021-12-31 | 14.4% | — |
Pre-Tax Margin vs competitors
How RCUS compares with its peers on the latest reported figures
- RCUS's LTM Jun 2026 pre-tax margin of -386.3% is the 3rd highest of the 8 companies compared; the peer median is -558.2%.
- Its year-over-year change of -269.5 pp is the 6th highest of 7, against a peer median of +210.5 pp.
- Over three fiscal years its change of +94.6 pp compares with a peer median of +636.8 pp.
| Company | Period | LTM level | YoY | 3-year change |
|---|---|---|---|---|
| LTM Jun 2026 | 33.2% | +765.3 pp | +213.9 pp | |
| LTM Jun 2026 | -54.7% | +606.6 pp | +411.7 pp | |
| LTM Jun 2026 | -386.3% | -269.5 pp | +94.6 pp | |
| LTM Jun 2026 | -544.1% | +112262.8 pp | +6845.7 pp | |
| LTM Mar 2026 | -558.2% | -235.2 pp | -375.2 pp | |
| LTM Sep 2026 | -607.9% | -185.5 pp | +173558.8 pp | |
| LTM Mar 2026 | -641.4% | -2559.1 pp | +861.9 pp | |
| LTM Jun 2026 | -14188.4% | — | — | |
| FY2025 | — | — | — | |
| Peer median (excluding RCUS) | -558.2% | +210.5 pp | +636.8 pp | |
Competitors are the stored peer set for RCUS. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 383M | 112M | 117M | 258M | 247M |
| Cost of Revenue | 0 | 0 | 0 | 0 | 10M |
| Gross Profit | 383M | 112M | 117M | 258M | 237M |
| Gross Margin | 100.0% | 100.0% | 100.0% | 100.0% | 96.0% |
| Research & Development | 257M | 288M | 340M | 448M | 523M |
| Selling, General & Admin | 72M | 104M | 117M | 120M | 110M |
| Operating Expenses | 329M | 392M | 457M | 588M | 623M |
| Depreciation & Amortization | 4M | 6M | 8M | 10M | 10M |
| EBITDA | 59M | (258M) | (291M) | (269M) | (335M) |
| EBITDA Margin | 15.4% | -230.4% | -248.7% | -104.3% | -135.6% |
| Operating Income | 54M | (280M) | (340M) | (330M) | (386M) |
| Operating Margin | 14.1% | -250.0% | -290.6% | -127.9% | -156.3% |
| Interest Income | 1M | 16M | 41M | 52M | 41M |
| Interest Expense | 0 | 2M | 2M | 4M | 8M |
| Other Income / Expenses | 1M | 14M | 39M | 47M | 33M |
| Income Before Tax | 55M | (266M) | (301M) | (283M) | (353M) |
| Pre-Tax Margin | 14.4% | -237.5% | -257.3% | -109.7% | -142.9% |
| Income Tax Expense | 2M | 1M | 6M | 1M | 0 |
| Net Income | 53M | (267M) | (307M) | (283M) | (353M) |
| Net Margin | 13.8% | -238.4% | -262.4% | -109.7% | -142.9% |
| EPS (Basic) | 0.76 | (3.71) | (4.15) | (3.14) | (3.29) |
| EPS (Diluted) | 0.71 | (3.71) | (4.15) | (3.14) | (3.29) |
| Weighted Avg Shares | 69.35M | 72M | 74M | 90.1M | 107.4M |
| Weighted Avg Shares (Diluted) | 73.97M | 72M | 74M | 90.1M | 107.4M |
Arcus Biosciences, Inc.
NYSE:RCUS
Intrinsic Alpha fair value
Locked
Current Price
$15.76
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.